Literature DB >> 10071047

Transthyretin Leu12Pro is associated with systemic, neuropathic and leptomeningeal amyloidosis.

M Brett1, M R Persey, M M Reilly, T Revesz, D R Booth, S E Booth, P N Hawkins, M B Pepys, J A Morgan-Hughes.   

Abstract

We report a middle-aged woman with a novel transthyretin (TTR) variant, Leu12Pro. She had extensive amyloid deposition in the leptomeninges and liver as well as the involvement of the heart and peripheral nervous system which characterizes familial amyloid polyneuropathy caused by variant TTR. Clinical features attributed to her leptomeningeal amyloid included radiculopathy, central hypoventilation, recurrent subarachnoid haemorrhage, depression, seizures and periods of decreased consciousness. MRI showed a marked enhancement throughout her meninges and ependyma, and TTR amyloid deposition was confirmed by meningeal biopsy. The simultaneous presence of extensive visceral amyloid and clinically significant deposits affecting both the peripheral and central nervous system extends the spectrum of amyloid-related disease associated with TTR mutations. The unusual association of severe peripheral neuropathy with symptoms of leptomeningeal amyloid indicates that leptomeningeal amyloidosis should be considered part of the syndrome of TTR-related familial amyloid polyneuropathy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10071047     DOI: 10.1093/brain/122.2.183

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  18 in total

1.  Transthyretin-related familial amyloid polyneuropathy: evaluation of CSF enhancement on serial T1-weighted and fluid-attenuated inversion recovery images following intravenous contrast administration.

Authors:  Toshinori Hirai; Yukio Ando; Masayuki Yamura; Mika Kitajima; Yoshiko Hayashida; Yukunori Korogi; Taro Yamashita; Yasuyuki Yamashita
Journal:  AJNR Am J Neuroradiol       Date:  2005-09       Impact factor: 3.825

2.  Leptomeningeal familial amyloidosis: A rare differential diagnosis of leptomeningeal enhancement in MRI.

Authors:  P P Urban; C Hertkorn; J M Schattenberg; J Gawehn; S Hägele; M Wunsch; K Altland
Journal:  J Neurol       Date:  2006-09-21       Impact factor: 4.849

Review 3.  Cerebrovascular disorders associated with genetic lesions.

Authors:  Philipp Karschnia; Sayoko Nishimura; Angeliki Louvi
Journal:  Cell Mol Life Sci       Date:  2018-10-16       Impact factor: 9.261

Review 4.  Amyloid neuropathies.

Authors:  Susan C Shin; Jessica Robinson-Papp
Journal:  Mt Sinai J Med       Date:  2012 Nov-Dec

Review 5.  Current and future treatment of amyloid diseases.

Authors:  M Ankarcrona; B Winblad; C Monteiro; C Fearns; E T Powers; J Johansson; G T Westermark; J Presto; B-G Ericzon; J W Kelly
Journal:  J Intern Med       Date:  2016-05-10       Impact factor: 8.989

6.  The identification of a transthyretin variant p.D38G in a Chinese family with early-onset leptomeningeal amyloidosis.

Authors:  Kuan Fan; Haixia Zhu; Hongbo Xu; Ping Mao; Lamei Yuan; Hao Deng
Journal:  J Neurol       Date:  2018-11-23       Impact factor: 4.849

7.  Familial amyloidotic polyneuropathy with muscle, vitreous, leptomeningeal, and cardiac involvement: phenotypic, pathological, and MRI description.

Authors:  D K Prashantha; Arun B Taly; Sanjib Sinha; T Chikkabasavaiah Yasha; Narayanappa Gayathri; J M E Kovur; Joy Vijayan
Journal:  Ann Indian Acad Neurol       Date:  2010-04       Impact factor: 1.383

Review 8.  Amyloidosis in Heart Failure.

Authors:  Sandra Ihne; Caroline Morbach; Laura Obici; Giovanni Palladini; Stefan Störk
Journal:  Curr Heart Fail Rep       Date:  2019-12

9.  Early onset vitreous amyloidosis in familial amyloidotic polyneuropathy with a transthyretin Glu54Gly mutation is associated with elevated vitreous VEGF.

Authors:  T M O'Hearn; A Fawzi; S He; N A Rao; J I Lim
Journal:  Br J Ophthalmol       Date:  2007-05-23       Impact factor: 4.638

10.  A novel amyloidogenic transthyretin variant, Gly53Ala, associated with intermittent headaches and ataxia.

Authors:  C Douglass; K Suvarna; M M Reilly; P N Hawkins; M Hadjivassiliou
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-09-13       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.